Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
In the European Crohn's and Colitis Organisation (ECCO) paper of 2006 (Gut 2006;55(Suppl 1):i1–15), consensus on the diagnosis of Crohn’s disease was described. However, we were surprised that nothing was mentioned about the association between the use of mycophenolate mofetil (MMF, Cellcept) and the occurrence of Crohn’s-like enterocolitis.
MMF is widely used to prevent rejection after solid organ transplantation. The active compound, mycophenolic acid (MPA), is a reversible, non-competitive inhibitor of inosine monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme in de novo purine biosynthesis in T and B lymphocytes. The most common adverse drug reactions of MMF are gastro-intestinal complaints.1–3 In 2003, a prospective cohort study including 26 renal transplant recipients with persistent diarrhoea showed for the first time that in patients using MMF, Crohn’s-like enterocolitis could …
Competing interests: None.
Patient consent: Obtained.